Health

RSV Passive Immunization 69% Effective in Protecting Infants

RSV Passive Immunization 69% Effective in Protecting Infants

February 10, 2024 • 6:15 am CST

Eurosurveillance paediatric hospital, Luxembourg, 2022–2023

The journal Eurosurveillance Rapid Communication published a study on January 25, 2024, that concluded Beyfortus™ (Nirsevimab) was about 69% effective at preventing pediatric respiratory syncytial virus (RSV) hospitalizations in infants.

In the context of moderate to high immunization coverage (84%) among neonates, this study provides early real-world evidence of nirsevimab immunization protecting infants from severe RSV disease in Luxembourg.

In 2023, 241 children under five years of age were hospitalized with a laboratory-confirmed RSV infection, compared with 389 cases in 2022, representing decreases of 38% (389 vs. 241) in cases under five years of age and 69% (232 vs. 72) in cases of infants under six months old.

The researchers concluded, ‘Our study shows the impact of nirsevimab in mitigating severe RSV disease among infants during the first RSV season following the national implementation of passive immunization achieving high coverage in Luxembourg. There was a significant increase in the age of hospitalized children, and most severe RSV-related hospitalizations occurred in non-immunized children.’

In previous clinical trials, nirsevimab showed between 74% and 86% efficacy against medically-attended lower respiratory tract infections caused by RSV in healthy infants.

As of February 2024, Beyfortus’s availability in the U.S. has significantly improved.

Our Trust Standards: Medical Advisory Committee

National Public Health Strategy Released to Prevent and Control Vector-Borne Diseases

Trivalent Flu Shot Formulations Coming Next Season

RSV, COVID-19, Flu Hospitalizations Declining in February 2024

Are Yellow Fever Vaccine Boosters Needed

School Vaccinations Increased When Nonmedical Exemptions Were Eliminated

Bladder Cancer Vaccine Therapy Offers Favorable Risk-Benefit Ratio

HIV Vaccine Research Rekindles in 2024

Congenital Syphilis Cases Increased 30% Without a Preventive Vaccine

64% More Measles Cases Last Year

Pregnant Women Prefer RSV Passive Immunization Protection for Infants

Texas Publishes ‘Big Three’ Respiratory Virus Trends and Insights

Houston’s Flu and RSV Season Fizzles Out

Immunize Infants with Beyfortus As Quickly As Possible

Infants Protected From RSV Hospitalizations With Passive Immunization

RSV and Flu Vaccine Coadministration Found Safe

U.S. Government Wants Additional RSV Passive Immunization Supply

3.4% of Expecting Mothers Infected With RSV

RSV Vaccination May Protect Seniors from Hospitalization

4th Vaccine Approved for Pregnant Women

Expecting Mothers Have RSV Prevention Options

RSV Vaccine Now Ava

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *